메뉴 건너뛰기




Volumn 30, Issue 4, 2005, Pages 332-338

Can PCI with drug-eluting stents replace coronary artery bypass surgery? A comparative economic analysis regarding both therapeutic options based on clinical 12-month data reflecting the german social health care insurance system;Können medikamente freisetzende koronarstents eine bypassoperation ersetzen? Ein gesundheitsökonomischer vergleich beider therapieformen auf der basis klinischer 12-monats-daten

Author keywords

Coronary bypass surgery; Costs; Restenosis; Stent

Indexed keywords

CLOPIDOGREL;

EID: 21544466716     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-005-2694-5     Document Type: Article
Times cited : (3)

References (22)
  • 1
    • 0344825229 scopus 로고    scopus 로고
    • Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina: Review of the evidence and methodological considerations
    • Rihal CS, Raco DL, Gersh BJ, et al. Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina: review of the evidence and methodological considerations. Circulation 2003;108:2439-45.
    • (2003) Circulation , vol.108 , pp. 2439-2445
    • Rihal, C.S.1    Raco, D.L.2    Gersh, B.J.3
  • 2
    • 0035849152 scopus 로고    scopus 로고
    • Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease
    • Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-24.
    • (2001) N Engl J Med , vol.344 , pp. 1117-1124
    • Serruys, P.W.1    Unger, F.2    Sousa, J.E.3
  • 3
    • 4644317869 scopus 로고    scopus 로고
    • Wann sind Drug-eluting Stents als wirksam zu bezeichnen? Eine kritische Analyse der aktuellen Datenlage
    • Silber S. Wann sind Drug-eluting Stents als wirksam zu bezeichnen? Eine kritische Analyse der aktuellen Datenlage. Z Kardiol 2004;93:649-63.
    • (2004) Z Kardiol , vol.93 , pp. 649-663
    • Silber, S.1
  • 4
    • 4344595775 scopus 로고    scopus 로고
    • Sirolimus eluting stent implantation for patients with multivessel disease: Rationale for the Arterial Revascularisation Therapies Study part II (ARTS II)
    • Serruys PW, Lemos PA, van Hout BA. Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II). Heart 2004;90:995-8.
    • (2004) Heart , vol.90 , pp. 995-998
    • Serruys, P.W.1    Lemos, P.A.2    Van Hout, B.A.3
  • 5
    • 3543064732 scopus 로고    scopus 로고
    • Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: Results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions (SIRIUS) trial
    • Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 2004;110:508-14.
    • (2004) Circulation , vol.110 , pp. 508-514
    • Cohen, D.J.1    Bakhai, A.2    Shi, C.3
  • 6
    • 3543096366 scopus 로고    scopus 로고
    • Economics of sirolimus-eluting stents: Drug-eluting stents have really arrived
    • Weintraub WS. Economics of sirolimus-eluting stents: drug-eluting stents have really arrived. Circulation 2004;110:472-4.
    • (2004) Circulation , vol.110 , pp. 472-474
    • Weintraub, W.S.1
  • 7
    • 2342423261 scopus 로고    scopus 로고
    • Economic impact of drug-eluting stents on hospital systems: A disease-state model
    • Kong DF, Eisenstein EL, Sketch MH Jr, et al. Economic impact of drug-eluting stents on hospital systems: a disease-state model. Am Heart J 2004;147:449-56.
    • (2004) Am Heart J , vol.147 , pp. 449-456
    • Kong, D.F.1    Eisenstein, E.L.2    Sketch Jr., M.H.3
  • 8
    • 21544456058 scopus 로고    scopus 로고
    • Cost-effectiveness of drug-eluting coronary artery stenting in a UK setting: Cost-utility study
    • in press
    • Bagust A, Grayson AD, Palmer ND, et al. Cost-effectiveness of drug-eluting coronary artery stenting in a UK setting: cost-utility study. Heart 2005: in press.
    • (2005) Heart
    • Bagust, A.1    Grayson, A.D.2    Palmer, N.D.3
  • 9
    • 15844430483 scopus 로고    scopus 로고
    • One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: An analysis from the RAVEL trial
    • Van Hout BA, Serruys PW, Lemos PA, et al. One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial. Heart 2005;91:507-12.
    • (2005) Heart , vol.91 , pp. 507-512
    • Van Hout, B.A.1    Serruys, P.W.2    Lemos, P.A.3
  • 10
    • 13544260983 scopus 로고    scopus 로고
    • What reimbursement for coronary revascularization with drug-eluting stents?
    • Tarricone R, Marchetti M, Lamotte M, et al. What reimbursement for coronary revascularization with drug-eluting stents? Eur J Health Econ 2004;5:309-16.
    • (2004) Eur J Health Econ , vol.5 , pp. 309-316
    • Tarricone, R.1    Marchetti, M.2    Lamotte, M.3
  • 14
    • 0035979350 scopus 로고    scopus 로고
    • Clinical and economic impact of diabetes mellituson percutaneous and surgical treatment of multivessel coronary disease patients: Insights from the Arterial Revascularization Therapy Study (ARTS) trial
    • Abizaid A, Costa MA, Centemero M, et al. Clinical and economic impact of diabetes mellituson percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 2001;104:533-8.
    • (2001) Circulation , vol.104 , pp. 533-538
    • Abizaid, A.1    Costa, M.A.2    Centemero, M.3
  • 15
    • 4143135288 scopus 로고    scopus 로고
    • Feasibility and cost of treatment with drug eluting stents of surgical candidates with multi-vessel coronary disease
    • Griffiths H, Bakhai A, West D, et al. Feasibility and cost of treatment with drug eluting stents of surgical candidates with multi-vessel coronary disease. Eur J Cardiothorac Surg 2004;26:528-34.
    • (2004) Eur J Cardiothorac Surg , vol.26 , pp. 528-534
    • Griffiths, H.1    Bakhai, A.2    West, D.3
  • 16
    • 0041355955 scopus 로고    scopus 로고
    • The Boston Scientific Antiproliferative, Paclitaxel Eluting Stents (TAXUS)
    • Serruys P, Kutryk M, eds. London: Dunitz
    • Silber S, Grube E. The Boston Scientific Antiproliferative, Paclitaxel Eluting Stents (TAXUS). In: Serruys P, Kutryk M, eds. Handbook of Coronary Stents, 4th edn. London: Dunitz, 2001:311-9.
    • (2001) Handbook of Coronary Stents, 4th Edn. , pp. 311-319
    • Silber, S.1    Grube, E.2
  • 17
    • 11144355008 scopus 로고    scopus 로고
    • Direct stenting with TAXUS stents seems to be as safe and effective as with predilatation:a post hoc analysis of TAXUS II
    • Silber S, Hamburger J, Grube E, et al. Direct stenting with TAXUS stents seems to be as safe and effective as with predilatation:a post hoc analysis of TAXUS II. Herz 2004;29:171-80.
    • (2004) Herz , vol.29 , pp. 171-180
    • Silber, S.1    Hamburger, J.2    Grube, E.3
  • 18
    • 0042388295 scopus 로고    scopus 로고
    • Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions
    • Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
    • (2003) Circulation , vol.108 , pp. 788-794
    • Colombo, A.1    Drzewiecki, J.2    Banning, A.3
  • 19
    • 9144249927 scopus 로고    scopus 로고
    • A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease
    • Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
    • (2004) N Engl J Med , vol.350 , pp. 221-231
    • Stone, G.W.1    Ellis, S.G.2    Cox, D.A.3
  • 20
    • 0037394555 scopus 로고    scopus 로고
    • A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: One- to eight-year outcomes
    • Hoffman SN, TenBrook JA, Wolf MP, et al. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes. J Am Coll Cardiol 2003;41:1293-304.
    • (2003) J Am Coll Cardiol , vol.41 , pp. 1293-1304
    • Hoffman, S.N.1    TenBrook, J.A.2    Wolf, M.P.3
  • 21
    • 0141954178 scopus 로고    scopus 로고
    • Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: One-year results from the Stent or Surgery trial
    • Zhang Z, Mahoney EM, Stables RH, et al. Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: one-year results from the Stent or Surgery trial. Circulation 2003;108:1694-700.
    • (2003) Circulation , vol.108 , pp. 1694-1700
    • Zhang, Z.1    Mahoney, E.M.2    Stables, R.H.3
  • 22
    • 20244377701 scopus 로고    scopus 로고
    • Guidelines for percutaneous coronary interventions: The Task Force for Percutaneous Coronary linterventions of the European Society of Cardiology
    • Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions: the Task Force for Percutaneous Coronary linterventions of the European Society of Cardiology. Eur Heart J 2005;26:804-47.
    • (2005) Eur Heart J , vol.26 , pp. 804-847
    • Silber, S.1    Albertsson, P.2    Aviles, F.F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.